WO2006123226A3 - An inhibitor of mtor for inhibiting the formation of scar tissue - Google Patents

An inhibitor of mtor for inhibiting the formation of scar tissue Download PDF

Info

Publication number
WO2006123226A3
WO2006123226A3 PCT/IB2006/001300 IB2006001300W WO2006123226A3 WO 2006123226 A3 WO2006123226 A3 WO 2006123226A3 IB 2006001300 W IB2006001300 W IB 2006001300W WO 2006123226 A3 WO2006123226 A3 WO 2006123226A3
Authority
WO
WIPO (PCT)
Prior art keywords
surgery
disease
mtor
impregnated
prevent
Prior art date
Application number
PCT/IB2006/001300
Other languages
French (fr)
Other versions
WO2006123226A2 (en
Inventor
Hugo Barrie Nel
Original Assignee
Villiers Malan De
Hugo Barrie Nel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Villiers Malan De, Hugo Barrie Nel filed Critical Villiers Malan De
Publication of WO2006123226A2 publication Critical patent/WO2006123226A2/en
Publication of WO2006123226A3 publication Critical patent/WO2006123226A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The invention describes the use of an inhibitor of the mammalian Target of Rapamycin (mTOR), such as sirolimus or everolimus, to effect a clinical response on an insult or wound. The compound can be administered in any suitable local or topical delivery form, such as by local injection; local delivery systems, for example impregnated implants and slow release devices; forms of dressings, impregnated suturing material; impregnated mesh, sheets, membranes, prosthetics; gels containing the compound; and so forth. Typical applications where it would be useful to prevent scarring by inhibiting the mTOR according to the invention are: cosmetic surgery; scar revision surgery, including excision of scars and contracture release; tendon repair; nerve repair; and fibrotic or inflammatory conditions, such as de Quervain's disease, Peyronie's disease, plantar fasciitis, Dupuytren's disease, finger triggering, forms of synovitis, such as rheumatoid arthritis, after laparotomy to prevent adhesions, after brain surgery to prevent gliosis, and microsurgery, such as microvascular surgery and fallopian tube surgery.
PCT/IB2006/001300 2005-05-18 2006-05-18 An inhibitor of mtor for inhibiting the formation of scar tissue WO2006123226A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68258105P 2005-05-18 2005-05-18
US60/682,581 2005-05-18
ZA200504008 2005-05-18
ZA2005/04008 2005-05-18

Publications (2)

Publication Number Publication Date
WO2006123226A2 WO2006123226A2 (en) 2006-11-23
WO2006123226A3 true WO2006123226A3 (en) 2007-01-11

Family

ID=36968953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001300 WO2006123226A2 (en) 2005-05-18 2006-05-18 An inhibitor of mtor for inhibiting the formation of scar tissue

Country Status (1)

Country Link
WO (1) WO2006123226A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009030931A1 (en) 2009-06-24 2010-12-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Surgical wound sealing element for sealing wound in surgical joint in e.g. intestine of human, has body coated with anti-inflammatory composition and designed as thread that comprises fibers, which are interlaced together
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
DK2948134T3 (en) 2013-01-24 2020-06-02 Palvella Therapeutics Inc COMPOSITIONS FOR TRANSDERMAL ADMINISTRATION OF MTOR INHIBITORS
PL3030232T3 (en) * 2013-04-29 2022-11-07 Medregen, Llc Wound healing via autologous stem cell mobilization
HUP1400075A2 (en) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical composition containing them
WO2016130485A1 (en) * 2015-02-09 2016-08-18 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to prevent and regress adhesions and fibrosis
CA3049402A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087613A1 (en) * 2002-01-29 2004-05-06 Molmenti Ernesto P. Prevention of adhesions with rapamycin
WO2004110347A2 (en) * 2003-05-07 2004-12-23 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20040087613A1 (en) * 2002-01-29 2004-05-06 Molmenti Ernesto P. Prevention of adhesions with rapamycin
WO2004110347A2 (en) * 2003-05-07 2004-12-23 Afmedica, Inc. Compositions and methods for reducing scar tissue formation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM A ET AL: "Are keloids really "gli-loids"?: High-level expression of gli-1 oncogene in keloids.", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. NOV 2001, vol. 45, no. 5, November 2001 (2001-11-01), pages 707 - 711, XP002399754, ISSN: 0190-9622 *

Also Published As

Publication number Publication date
WO2006123226A2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
WO2006123226A3 (en) An inhibitor of mtor for inhibiting the formation of scar tissue
MXPA03003906A (en) Surgically implanted devices having reduced scar tissue.
BRPI0515191A (en) pharmaceutical composition, method for augmenting bone or replacing bone loss, method for reducing pain associated with postoperative scarring, method for preventing surgical adhesion, method for enlarging or repairing skin or tissue, method for maintaining eye fluid volume during eye surgery , method for reducing pain associated with osteoarthritis, method for treating gastroesophageal reflux disease, method for treating or preventing urinary incontinence, method for treating or preventing fecal incontinence, implant method and medical device
Williams et al. Poly-4-hydroxybutyrate (P4HB): a new generation of resorbable medical devices for tissue repair and regeneration
Berger et al. Polyvinylidene fluoride: a suitable mesh material for laparoscopic incisional and parastomal hernia repair! A prospective, observational study with 344 patients
Verhorstert et al. In vitro bacterial adhesion and biofilm formation on fully absorbable poly-4-hydroxybutyrate and nonabsorbable polypropylene pelvic floor implants
DE602006018460D1 (en) ACTIVE INGREDIENT FOR IMPLANTABLE INCONTINENCE DEVICES
WO2008057344A3 (en) Coated surgical mesh
WO2005112587A3 (en) Wound healing polymer compositions and methods for use thereof
ATE532540T1 (en) MODULAR BIORESORBABLE OR BIOMEDICAL BIOLOGICALLY ACTIVE SUPRAMOLECULAR SUBSTANCES
RU2006126779A (en) PHARMACEUTICAL COMPOSITIONS
WO2009113972A3 (en) Temporarily stiffened mesh prostheses
WO2005011770A3 (en) Biologically absorbable coatings for implantable devices
WO2007056134A3 (en) Resorbable phenolic polymers
WO2005055958A3 (en) Improved surgical adhesive and uses therefor
BRPI0512604A (en) Drug therapy in combination to reduce scar tissue formation
WO2006096517A3 (en) Adjustable access device for surgical procedures
WO2009064963A3 (en) Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
WO2006135479A2 (en) Anti-scarring agents, therapeutic compositions, and use thereof
WO2007127790A3 (en) Methods and compositions for the treatment of open and closed wound spinal cord injuries
WO2006002430A3 (en) Surgical instrumentation for the repair of vertebral bodies
Petter-Puchner et al. Adverse effects of porcine small intestine submucosa implants in experimental ventral hernia repair
WO2007139760A3 (en) Resorbable polymer compositions for use in medicine, dentistry, and surgery
Ersoy et al. Comparison of the two types of bioresorbable barriers to prevent intra-abdominal adhesions in rats
WO2011056593A3 (en) Systems and methods for tissue retraction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06744723

Country of ref document: EP

Kind code of ref document: A2